Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized, double-blind, placebo-controlled study of enpatoran in systemic and cutaneous lupus erythematosus
jRCT2031210627Phase 2Completed
- Sponsor
- Merck KGaA
- Start
- Jun 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of enpatoran in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), subacute cutaneous lupus erythematosus (SCLE) and 1 more (9 cohorts), sponsored by Merck KGaA. Primary endpoints: Dose–response relationship of enpatoran on CLASI-A and Dose–response relationship of enpatoran on BICLA response rate. Started Jun 2022; status: completed.
02
Drugs
enpatoran
03
Conditions
systemic lupus erythematosus (SLE)cutaneous lupus erythematosus (CLE)subacute cutaneous lupus erythematosus (SCLE)discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on jRCT2031210627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210627.